{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:39:27Z","timestamp":1788503967992,"version":"build-2803163510"},"reference-count":65,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antiphospholipid syndrome (APS) is defined by clinical manifestations that include thrombosis and\/or fetal loss or pregnancy morbidity in patients with antiphospholipid antibodies (aPL). Antiphospholipid antibodies are among the most common causes of acquired thrombophilia, but unlike most of the genetic thrombophilias are associated with both venous and arterial thrombosis. Despite an abundance of clinical and basic research on aPL, a unified mechanism that explains their prothrombotic activity has not been defined; this may reflect the heterogeneity of aPL and\/or the fact that they may influence multiple pro- and\/or antithrombotic pathways. Antiphospholipid antibodies are directed primarily toward phospholipid binding proteins rather than phospholipid per se, with the most common antigenic target being \u03b22-glycoprotein 1 (\u03b22GPI) although antibodies against other targets such as prothrombin are well described. Laboratory diagnosis of aPL depends upon the detection of a lupus anticoagulant (LA), which prolongs phospholipid-dependent anticoagulation tests, and\/or anticardiolipin and anti-\u03b22-glycoprotein 1 antibodies. Indefinite anticoagulation remains the mainstay of therapy for thrombotic APS, although new strategies that may improve outcomes are emerging. Preliminary reports suggest caution in the use of direct oral anticoagulants in patients with APS-associated thrombosis. Based on somewhat limited evidence, aspirin and low molecular weight heparin are recommended for obstetrical APS. There remains a pressing need for better understanding of the pathogenesis of APS in humans, for identification of clinical and laboratory parameters that define patients at greatest risk for APS-related events, and for targeted treatment of this common yet enigmatic disorder.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.53","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["The antiphospholipid syndrome: still an enigma"],"prefix":"10.1182","volume":"2015","author":[{"given":"Shruti","family":"Chaturvedi","sequence":"first","affiliation":[{"name":"Division of Hematology, Vanderbilt University Medical Center, Nashville, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[{"name":"Hematology and Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111706091759600_B1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111706091759600_B2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2019111706091759600_B3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"issue":"6","key":"2019111706091759600_B4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2019111706091759600_B5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0032-1304718","article-title":"Update on the catastrophic antiphospholipid syndrome and the \u201cCAPS Registry\u201d","volume":"38","author":"Cervera","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"2019111706091759600_B6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0961203309106833","article-title":"The CAPS Registry: morbidity and mortality of the catastrophic antiphospholipid syndrome","volume":"18","author":"Bucciarelli","year":"2009","journal-title":"Lupus"},{"issue":"4","key":"2019111706091759600_B7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111706091759600_B8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1160\/TH12-07-0527","article-title":"Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS\/PT) in patients with and without lupus anticoagulant","volume":"109","author":"Bertolaccini","year":"2013","journal-title":"Thromb Haemost"},{"issue":"26","key":"2019111706091759600_B9","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1073\/pnas.95.26.15542","article-title":"Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI","volume":"95","author":"Iverson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2019111706091759600_B10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"Agar","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111706091759600_B11","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)","volume":"87","author":"McNeil","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111706091759600_B12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood-2009-09-244426","article-title":"Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants","volume":"115","author":"Devreese","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111706091759600_B13","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2004-01-0203","article-title":"Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome","volume":"104","author":"Rand","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111706091759600_B14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood-2006-10-053199","article-title":"beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation","volume":"110","author":"Hulstein","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111706091759600_B15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111706091759600_B16","first-page":"3453","article-title":"Neutrophil activation by the tissue factor\/Factor VIIa\/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome","volume":"118","author":"Redecha","year":"2008","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111706091759600_B17","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection: Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111706091759600_B18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1055\/s-0033-1364207","article-title":"Standardization of antiphospholipid antibody testing\u2013historical perspectives and ongoing initiatives","volume":"40","author":"Willis","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2019111706091759600_B19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH10-08-0511","article-title":"Rivaroxaban and false positive lupus anticoagulant testing","volume":"105","author":"Merriman","year":"2011","journal-title":"Thromb Haemost"},{"issue":"4","key":"2019111706091759600_B20","first-page":"583","article-title":"Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment.: performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA","volume":"88","author":"Tripodi","year":"2002","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111706091759600_B21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ijlh.12138","article-title":"Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","volume":"36","author":"Martinuzzo","year":"2014","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2019111706091759600_B22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-0033-1364185","article-title":"Recent guidelines and recommendations for laboratory detection of lupus anticoagulants","volume":"40","author":"Moore","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2019111706091759600_B23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MBC.0b013e3283256037","article-title":"The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist","volume":"20","author":"Parmar","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"2019111706091759600_B24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1538-7836.2011.04395.x","article-title":"Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time","volume":"9","author":"van Os","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2019111706091759600_B25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1538-7836.2010.04068.x","article-title":"An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies","volume":"9","author":"De Laat","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111706091759600_B26","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004","journal-title":"Blood"},{"issue":"11","key":"2019111706091759600_B27","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"issue":"2","key":"2019111706091759600_B28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.blre.2010.12.001","article-title":"Antiphospholipid antibodies: we are not quite there yet","volume":"25","author":"Urbanus","year":"2011","journal-title":"Blood Rev"},{"issue":"6","key":"2019111706091759600_B29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1373\/clinchem.2009.133678","article-title":"Challenges in the diagnosis of the antiphospholipid syndrome","volume":"56","author":"Devreese","year":"2010","journal-title":"Clin Chem"},{"issue":"9","key":"2019111706091759600_B30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111706091759600_B31","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2019111706091759600_B32","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203314545410","article-title":"Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study","volume":"23","author":"Mustonen","year":"2014","journal-title":"Lupus"},{"issue":"4","key":"2019111706091759600_B33","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2004-09-3387","article-title":"IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis","volume":"105","author":"de Laat","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2019111706091759600_B34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study","volume":"7","author":"de Laat","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111706091759600_B35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jth.12865","article-title":"Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk","volume":"13","author":"Pengo","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111706091759600_B36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood-2013-02-485839","article-title":"The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic","volume":"122","author":"Clark","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111706091759600_B37","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/art.34402","article-title":"Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies","volume":"64","author":"Lockshin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2019111706091759600_B38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1538-7836.2010.03747.x","article-title":"Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies","volume":"8","author":"Chauleur","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2019111706091759600_B39","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111706091759600_B40","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2019111706091759600_B41","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","article-title":"Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review","volume":"122","author":"Garcia","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2019111706091759600_B42","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1055\/s-0028-1082271","article-title":"Pediatric antiphospholipid antibodies and antiphospholipid syndrome","volume":"34","author":"Hunt","year":"2008","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2019111706091759600_B43","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.291.5.576","article-title":"Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke","volume":"291","author":"Levine","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"2019111706091759600_B44","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int J Med Sci"},{"issue":"5","key":"2019111706091759600_B45","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.thromres.2015.01.028","article-title":"The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases","volume":"135","author":"Son","year":"2015","journal-title":"Thromb Res"},{"issue":"5","key":"2019111706091759600_B46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1160\/th14-03-0272","article-title":"Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients","volume":"112","author":"Schaefer","year":"2014","journal-title":"Thromb Haemost"},{"issue":"10","key":"2019111706091759600_B47","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.23797","article-title":"New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome","volume":"89","author":"Win","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111706091759600_B48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"2019111706091759600_B49","doi-asserted-by":"crossref","first-page":"576.e577","DOI":"10.1016\/j.ajog.2011.06.064","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"2019111706091759600_B50","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111706091759600_B51","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2019111706091759600_B52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2019111706091759600_B53","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2019111706091759600_B54","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0002-9440(10)64044-8","article-title":"CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis","volume":"158","author":"Kim","year":"2001","journal-title":"Am J Pathol"},{"issue":"9","key":"2019111706091759600_B55","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2019111706091759600_B56","first-page":"Cd002859","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","author":"Empson","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2019111706091759600_B57","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1471-0528.1999.tb08208.x","article-title":"Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin","volume":"106","author":"Backos","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"issue":"7076","key":"2019111706091759600_B58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai","year":"1997","journal-title":"BMJ"},{"key":"2019111706091759600_B59","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"2","key":"2019111706091759600_B60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"issue":"9","key":"2019111706091759600_B61","first-page":"2006","article-title":"Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator","volume":"29","author":"Burcoglu-O'Ral","year":"2002","journal-title":"J Rheumatol"},{"issue":"2","key":"2019111706091759600_B62","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"issue":"7","key":"2019111706091759600_B63","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2019111706091759600_B64","first-page":"1560","article-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals","volume":"31","author":"Giron-Gonzalez","year":"2004","journal-title":"J Rheumatol"},{"issue":"11","key":"2019111706091759600_B65","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203315578765","article-title":"Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review","volume":"24","author":"Amengual","year":"2015","journal-title":"Lupus"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/53\/1250938\/bep00115000053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/53\/1250938\/bep00115000053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T15:27:35Z","timestamp":1657294055000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/53\/20708\/The-antiphospholipid-syndrome-still-an-enigma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.53","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}